N3-substituted imidazopyridine c-Kit inhibitors

A compound represented by Formula (I)

• wherein:
• R1 is —NR3R31, —NR3C(O)R31, —NR3C(O)OR31, —NR3SO2R31, —OR3, —SR3, —SO2R3, —CO2R3, —CO2H, —CO—NR3R31, —N(C0-8alkyl)(C0-8alkyl), or —CN, group;
• R2 is H, —C0-8alkyl, or —C3-10cycloalkyl;
• X is a cyclyl or heterocyclyl group optionally substituted with 1 or more substituents chosen from H, halogen, NR32R33, NR32COR33, NR32CO2R33, NR32SO2R33OR32, SR32, SO2R32, SO2NR32R33, CO2R32, CO2H, CONR32R33, —C0-8alkyl, —C2-8alkenyl, —C2-8alkynyl, CN, CF3, OCF3, NO2, oxo, cyclyl or a heterocyclyl group;
• Y is absent;
• wherein the point of attachment to X can be from either the left or the right of the linkers as shown;
• Z is a cyclyl or heterocyclyl group, optionally substituted with 1 or more substituents chosen from halogen, NR34R35, NR34COR35, NR34CO2R35, NR34SO2R35, OR34, SR34, SO2R34, SO2NR34R35, CO2R34, CO2H, CONR34R35, —C0-8alkyl, —C2-8alkenyl, —C2-8alkynyl, CN, CF3, NO2, oxo, cyclyl or a heterocyclyl group;
• and
• R3, R31, R32, R33, R34 and R35 are independently C0-8alkyl optionally substituted with a heterocyclyl or OH substituent;
• —C0-8alkyl-C3-8cycloalkyl, CF3, —C0-8alkyl-O—C0-8alkyl, —C0-8alkyl-N(C0-8alkyl)(C0-8alkyl), —C0-8alkyl-S(O)0-2—C0-8alkyl;
• or heterocyclyl optionally substituted with —C0-8alkyl, cyclyl or substituted cyclyl substituent;
• or a pharmaceutically acceptable salt or N-oxide thereof.